Featured Research

from universities, journals, and other organizations

UW Medical Center To Implant First-ever Cesium-131 Brachytherapy Seeds To Treat Prostate Cancer

Date:
November 2, 2004
Source:
University Of Washington
Summary:
In the first significant advancement in brachytherapy in more than 15 years, physicians at UW Medical Center have today (Oct. 26) implanted for the first time in the world a new type of radioactive seeds in a prostate cancer patient.

The dime shows the size of the radioactive seeds used in the implant procedure.
Credit: Photo Blayne Vixie / Courtesy of University Of Washington

In the first significant advancement in brachytherapy in more than 15 years, physicians at UW Medical Center have today (Oct. 26) implanted for the first time in the world a new type of radioactive seeds in a prostate cancer patient.

The cesium-131 (Cs-131) brachytherapy implant seed, developed by IsoRay of Richland, Wash., provides another viable option for men with prostate cancer, said Dr. Leroy Korb, assistant professor of radiation oncology at UW Medical Center.

"The Cs-131 seed developed by IsoRay offers a shorter half-life and faster delivery of the total radiation dose than the other types of seeds currently on the market," Korb said. "We believe it will be an effective option for men choosing brachytherapy to treat their prostate cancer."

The Cs-131 seed has a half-life of 9.7 days, compared to 60 days for iodine-125 seeds. It delivers more than 90 percent of its total radiation dose in less than 33 days.

"The new Cs-131 seed has a significantly higher dose rate than iodine, allowing for the delivery of more radiation in a shorter period of time to maximize its effectiveness," Korb said. "The treatment is over in one-sixth the time of iodine seeds and leaves the body 500 days faster."

Korb and Dr. William Ellis, professor of urology, will implant the first Cs-131 seeds in a 74-year-old Brookings, Ore., man in a procedure in UW Medical Center's new Surgery Pavilion. The procedure is completed in 45 to 60 minutes. Needles are used to implant the seeds, which are smaller than a grain of rice. No incision or suturing is required, and the patient usually doesn't need to stay overnight.

The patient is usually back to his normal work and daily activities within two to three days. After about three months, doctors will check to measure the effectiveness of the treatment.

Due to the shorter duration of treatment with Cs-131, side effects such as incontinence, urinary urgency or pain may be lessened, Korb said. Men who had good erectile function prior the implant should not experience any problems following the procedure.

Prostate cancer is one of the leading causes of death among men. About 230,000 men will be diagnosed with prostate cancer this year in the United States, and about 40,000 will die of the disease.

Ellis said that among patients in the UW prostate cancer program, about 50 percent have chosen surgery and the other 50 percent have chosen radiation treatment. Of the group that chose radiation, about 30 percent had external beam radiation and 20 percent had implanted seeds.

"We are very pleased to be the first to offer this new type of treatment at UW Medical Center and to partner with IsoRay, a Washington-based company," Korb said.


Story Source:

The above story is based on materials provided by University Of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University Of Washington. "UW Medical Center To Implant First-ever Cesium-131 Brachytherapy Seeds To Treat Prostate Cancer." ScienceDaily. ScienceDaily, 2 November 2004. <www.sciencedaily.com/releases/2004/10/041029105025.htm>.
University Of Washington. (2004, November 2). UW Medical Center To Implant First-ever Cesium-131 Brachytherapy Seeds To Treat Prostate Cancer. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2004/10/041029105025.htm
University Of Washington. "UW Medical Center To Implant First-ever Cesium-131 Brachytherapy Seeds To Treat Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2004/10/041029105025.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins